InVitro International (IVRO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - |
| Operating profit | $m | 0 | 0 | ||||||
| Net profit | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| EPS reported | $ | 0.01 | 0.00 | ||||||
| Operating cashflow per share | $ | -0.00 | 0.00 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.00 | 0.00 | ||||||
| Free cash flow | $m | -0 | -0 | ||||||
| Net debt | $m | -1 | -1 | ||||||
| Book value equity | $m | 2 | 2 | ||||||
| Book value per share | $ | 0.07 | 0.08 | ||||||
| Number of shares | m | 22.94 | 22.46 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 11.32 | 13.33 | ||||||
| P/B LTM | x | 0.82 | 0.80 | ||||||
| P/S LTM | x | 1.54 | 1.76 | ||||||
| P/FCF LTM | x | -156.26 | -12,330.01 | ||||||
| EV/EBITDA LTM | x | 7.56 | 18.36 | ||||||
| EV/Sales LTM | x | 1.11 | 1.03 | ||||||
| Earnings Yield LTM | % | +8.83% | +7.50% | ||||||
| FCF Yield | % | -0.64% | -0.01% | ||||||
| Quality | |||||||||
| ROE | % | +7.37% | +6.05% | ||||||
| ROIC | % | +4.42% | +3.57% | ||||||
| Operating margin | % | +9.90% | +8.60% | ||||||
| Gross margin | % | +81.70% | +81.83% | ||||||
| FCF/Sales | % | -0.99% | +1.42% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +17.78% | -22.22% | ||||||
| Sales Growth YoY | % | +8.34% | -4.96% | ||||||
| Net Income Growth YoY | % | +14.32% | -40.90% | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +27.40% | -49.73% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.03 | -0.00 | ||||||
| Net Debt/EBITDA | x | -2.92 | -9.87 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +4.67% | +3.72% | ||||||
| Net debt/Equity | x | -0.70 | -0.58 | ||||||
| Gross debt/equity | x | 0.17 | 0.14 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Established in 1985 and headquartered in Placentia, California, InVitro International specializes in creating and supplying non-animal testing kits to markets both within the United States and globally. Key among their offerings is the Irritection Assay System, an in vitro diagnostic tool designed to identify, categorize, and forecast the potential for eye and skin irritation across a broad spectrum of items, including cosmetics, general consumer products, pharmaceuticals, and various chemical raw materials. They also provide Corrositex, another in vitro test specifically for determining chemical corrosiveness. Beyond product sales, the company delivers tailored technological support for the implementation and use of the Irritection system, alongside offering independent laboratory services for irritation and corrosion assessments. Their solutions are predominantly adopted by manufacturers involved in producing surfactants, petrochemicals, cosmetics, textiles, paper and pulp, pharmaceuticals, films and resins, solvents and cleaners, and other chemical raw materials.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Established in 1985 and headquartered in Placentia, California, InVitro International specializes in creating and supplying non-animal testing kits to markets both within the United States and globally. Key among their offerings is the Irritection Assay System, an in vitro diagnostic tool designed to identify, categorize, and forecast the potential for eye and skin irritation across a broad spectrum of items, including cosmetics, general consumer products, pharmaceuticals, and various chemical raw materials. They also provide Corrositex, another in vitro test specifically for determining chemical corrosiveness. Beyond product sales, the company delivers tailored technological support for the implementation and use of the Irritection system, alongside offering independent laboratory services for irritation and corrosion assessments. Their solutions are predominantly adopted by manufacturers involved in producing surfactants, petrochemicals, cosmetics, textiles, paper and pulp, pharmaceuticals, films and resins, solvents and cleaners, and other chemical raw materials.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free